Vascular endothelial growth factor

Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) Drug Overview & Product Profiles 2019 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 26, 2019

VEGF production is upregulated in renal cell carcinoma and results in increased tumor vascularization and disease progression.

Key Points: 
  • VEGF production is upregulated in renal cell carcinoma and results in increased tumor vascularization and disease progression.
  • Standard first-line therapies such as Sutent (sunitinib; Pfizer) work by targeting VEGF/VEGFR signaling; however, tumors often develop resistance to these anti-angiogenic treatments.
  • Cabometyx's uptake has been strong, and this is set to continue with the drugs inclusion in combination therapies currently in development.
  • The Phase III CheckMate 9ER trial (ClinicalTrials.gov identifier: NCT03141177) is investigating the safety and efficacy of both Cabometyx + Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) doublet therapy and Cabometyx + Opdivo + Yervoy (ipilimumab; Bristol-Myers Squibb/Ono Pharmaceutical) triplet therapy.

MEI Pharma Presents Clinical Results for ME-344 in Combination with Bevacizumab in Early HER2 Negative Breast Cancer Patients at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Saturday, June 1, 2019

The clinical study was a multicenter, investigator-initiated, randomized, open-label trial evaluating ME-344 in a total of 42 patients with early HER2-negative breast cancer in combination with the vascular endothelial growth factor inhibitor bevacizumab.

Key Points: 
  • The clinical study was a multicenter, investigator-initiated, randomized, open-label trial evaluating ME-344 in a total of 42 patients with early HER2-negative breast cancer in combination with the vascular endothelial growth factor inhibitor bevacizumab.
  • Patients were randomized one-to-one to either ME-344 plus bevacizumab or saline plus bevacizumab.
  • MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer.
  • We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019

Retrieved on: 
Tuesday, April 30, 2019

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced data from a poster presentation on Monday, April 29, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019 in Vancouver, Canada.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced data from a poster presentation on Monday, April 29, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019 in Vancouver, Canada.
  • We remain committed to applying these learnings to bring forward in development a potential oral treatment for diabetic macular edema.
  • The poster presented data showing that two novel, orally administered plasma kallikrein inhibitors, KV998052 and KV998054, significantly reduce VEGF stimulated retinal edema in mice.
  • Oral administration of KV998054 initiated before VEGF injection resulted in a 59% (p=0.001) decrease in VEGF retinal thickening at 24 hours.

Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor Pipeline Insight, 2019 Report Featuring Genentech, OncoMed, & Roche - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 10, 2019

The "Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor development.
  • Descriptive coverage of pipeline development activities for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
  • The report assesses the active Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Intravitreal (IVT) Injectables Market is Expected to Rake in Revenues Worth US$ 4,350 Mn by 2028 End

Retrieved on: 
Thursday, March 14, 2019

Increasing prescription of anti-VEGF anticipate the growth of the intravitreal (IVT) injectables market.

Key Points: 
  • Increasing prescription of anti-VEGF anticipate the growth of the intravitreal (IVT) injectables market.
  • Low vision and blindness are prevailing in the region and high prescription of anti-VEGF intravitreal (IVT) injectables medication has increases the growth of intravitreal (IVT) injectables market.
  • It is estimated that intravitreal (IVT) injectables create an incremental $ opportunity worth US$ 4,350 Mn between 2018 and 2028.
  • The Global Intravitreal (IVT) Injectables Market has been segmented as presented below:
    Global Intravitreal (IVT) Injectables Market, By Geography:

Intravitreal (IVT) Injectables Market is Expected to Rake in Revenues Worth US$ 4,350 Mn by 2028 End

Retrieved on: 
Thursday, March 14, 2019

Increasing prescription of anti-VEGF anticipate the growth of the intravitreal (IVT) injectables market.

Key Points: 
  • Increasing prescription of anti-VEGF anticipate the growth of the intravitreal (IVT) injectables market.
  • Low vision and blindness are prevailing in the region and high prescription of anti-VEGF intravitreal (IVT) injectables medication has increases the growth of intravitreal (IVT) injectables market.
  • It is estimated that intravitreal (IVT) injectables create an incremental $ opportunity worth US$ 4,350 Mn between 2018 and 2028.
  • The Global Intravitreal (IVT) Injectables Market has been segmented as presented below:
    Global Intravitreal (IVT) Injectables Market, By Geography:

Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic

Retrieved on: 
Wednesday, February 20, 2019

The Phase 1a/b study, conducted with AstraZeneca, was a randomized, double-blind, placebo-controlled study in Europe of men with type 2 diabetes mellitus.

Key Points: 
  • The Phase 1a/b study, conducted with AstraZeneca, was a randomized, double-blind, placebo-controlled study in Europe of men with type 2 diabetes mellitus.
  • The VEGF-A mRNA was delivered in a saline solution and was administered by intradermal injection into forearm skin in single ascending doses.
  • These findings improve our understanding of the potential for Modernas mRNA to produce therapeutic levels of protein and help patients with a wide range of serious diseases.
  • A link to the publication, Intradermal Delivery of Modified mRNA Encoding VEGF-A in Patients with Type 2 Diabetes (Gan LM, et.

Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration

Retrieved on: 
Monday, August 13, 2018

EYLEA (aflibercept) Injection is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye.

Key Points: 
  • EYLEA (aflibercept) Injection is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye.
  • EYLEA is currently approved in wet AMD for every four- or eight-week dosing intervals after three initial monthly doses.
  • EYLEA (aflibercept) Injection is a prescription medication administered by injection into the eye.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection.

US FDA Approves Histogen IND for Female Hair Loss Trial

Retrieved on: 
Thursday, May 3, 2018

Hair Stimulating Complex (HSC660) is a soluble formulation of a subset of naturally-secreted growth factors developed as an injectable treatment for hair growth.

Key Points: 
  • Hair Stimulating Complex (HSC660) is a soluble formulation of a subset of naturally-secreted growth factors developed as an injectable treatment for hair growth.
  • Key growth factors within HSC660 include KGF, VEGF, and follistatin, which have been shown to be important in hair formation and the stimulation of resting hair follicles.
  • In addition to seeing a 100% female responder rate in the physician-sponsored study, previous trials have shown efficacy in other difficult-to-treat populations including men over 40 years of age and temporal recession hair loss.
  • Histogen is a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, including low oxygen and suspension.